Awarded contract

Oncotype DX Breast Cancer Testing

Details

Value
£272,700
Duration
1 year
Topic
Pathology services
Published
3 March 2026

Tender description

Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.

Timeline

  1. Completed: Award published3 March 2026
    Current notice
  2. Completed: Award date1 April 2026
  3. Next: Contract expiry date31 March 2027in 5 months

About the buyer

East Sussex Healthcare NHS Trust is a healthcare provider running acute and community services across East Sussex, with its own Procurement and Supplies Department. Conquest Hospital and Eastbourne District General Hospital are its two acute sites. Drug purchasing sits with the Pharmacy Department. NHS-to-NHS healthcare contracts are handled by the Contracts and Income team.

Over the past 5 years, most of East Sussex Healthcare NHS Trust's contract awards have been in health and social work, software and information systems and business services.

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

Finding public sector work shouldn't be hard

Make your next tender search effortless with Stotles. Set up alerts, find decision maker contacts and never miss a good-fit opportunity again.